What are the recommended treatments for mental health conditions like depression, anxiety, bipolar disorder, and schizophrenia?

Recommended Treatments for Mental Health Conditions

Depression

For moderate to severe depression, tricyclic antidepressants (TCAs) or fluoxetine should be the pharmacological treatment of choice, while antidepressants should NOT be used for mild depression. 1

Pharmacological Management by Severity

• Mild depression: Antidepressants are not recommended for initial treatment; instead, psychological interventions should be prioritized 1
• Moderate to severe depression: TCAs or fluoxetine are the recommended first-line antidepressants 1
• Duration of treatment: Antidepressant therapy must continue for 9-12 months after recovery to prevent relapse 1

Psychological Interventions

• First-line psychological treatments include interpersonal therapy, cognitive behavioral therapy (CBT) with behavioral activation, and problem-solving treatment 1
• These interventions can be delivered in non-specialized healthcare settings if sufficient human resources (e.g., supervised community health workers) are available 1
• For moderate and severe depression, problem-solving treatment should be used as adjunct treatment alongside other interventions 1

Adjunctive Interventions

• Relaxation training and advice on physical activity may be considered as treatment for depressive episodes 1
• In moderate and severe depression, these should be considered as adjunct treatments only 1

Critical Pitfall to Avoid

• Never use antidepressants or benzodiazepines for initial treatment of individuals with depressive symptoms in the absence of a current or prior depressive episode/disorder 1

---

Anxiety Disorders

Psychological treatment based on CBT principles is the recommended first-line approach for anxiety disorders, including panic attacks and PTSD. 1

Panic Attacks

• CBT-based psychological treatment should be offered to people concerned about prior panic attacks 1

Post-Traumatic Stress Disorder (PTSD)

• Acute phase (recent trauma): Provide access to support based on principles of psychological first aid for people in acute distress recently exposed to traumatic events 1
• Ongoing PTSD symptoms: Graded self-exposure based on CBT principles should be considered in adults with PTSD symptoms if follow-up is possible 1
• What NOT to do: Psychological debriefing should NOT be used for recent traumatic events to reduce risk of post-traumatic stress, anxiety, or depressive symptoms 1

Medically Unexplained Somatic Complaints with Anxiety

• CBT-based psychological treatment should be considered in repeat adult help seekers with medically unexplained somatic complaints who are in substantial distress and do not meet criteria for depressive episode/disorder 1

---

Bipolar Disorder

For acute mania, lithium, valproate, or haloperidol are recommended first-line treatments, with maintenance therapy continuing for at least 2 years after the last episode. 1

Acute Manic Episodes

• First-line medications: Haloperidol is recommended for bipolar mania 1
• Alternative options: Second-generation antipsychotics may be considered if availability can be assured and cost is not a constraint 1
• Mood stabilizers: Lithium, valproate, or carbamazepine should be offered to individuals with bipolar mania 1
• Important caveat: Lithium should only be initiated in settings where personnel and facilities for close clinical and laboratory monitoring are available 1

Maintenance Treatment

• Duration: Maintenance treatment should continue for at least 2 years after the last episode of bipolar disorder 1
• Preferred agents: Lithium or valproate should be used for maintenance treatment 1
• Decision to continue beyond 2 years should preferably be made by a mental health specialist 1

Bipolar Depression

• Antidepressants must ALWAYS be combined with a mood stabilizer (lithium or valproate) when treating moderate or severe depressive episodes of bipolar disorder 1
• Preferred antidepressant: SSRIs (fluoxetine) should be preferred over tricyclic antidepressants 1
• Critical warning: Antidepressant monotherapy is contraindicated due to risk of mood destabilization 2

Psychosocial Interventions

• Psychoeducation should be routinely offered to individuals with bipolar disorder and their family members/caregivers 1
• Additional options: CBT and family interventions can be considered if adequately trained professionals are available 1
• Psychosocial skills training: Interventions to enhance independent living and social skills should be considered, including social skills training in association with other psychosocial interventions 1

Pediatric Considerations

• For adolescents (ages 13-17): Lithium is the only FDA-approved agent for bipolar disorder, though atypical antipsychotics are commonly used 2
• Metabolic monitoring is critical: Atypical antipsychotics carry higher risk of weight gain and metabolic effects in adolescents 2
• When prescribing olanzapine to adolescents, clinicians should consider the increased potential for weight gain and dyslipidemia compared to adults, and in many cases this may lead them to consider prescribing other drugs first 3

---

Schizophrenia

Antipsychotic agents are the cornerstone of treatment for schizophrenia, with atypical antipsychotics preferred as first-line agents due to their efficacy and tolerability profile. 1

Pharmacological Management

• First-line agents: Both traditional neuroleptics (dopamine receptor blockers) and atypical antipsychotics (with serotonergic receptor antagonism) are recommended 1
• Atypical antipsychotics are preferred because they are at least as effective for positive symptoms as traditional agents 1
• Treatment-resistant schizophrenia: Clozapine has documented efficacy but is generally used only after therapeutic trials of at least two other antipsychotic medications (one or both should be an atypical agent) 1

Required Documentation and Monitoring

When using antipsychotic agents, the following are mandatory 1:

1. Adequate informed consent from parent/youth (depending on legal requirements)
2. Documentation of target symptoms
3. Documentation of baseline and follow-up laboratory monitoring
4. Documentation of treatment response
5. Documentation of suspected side effects, including monitoring for extrapyramidal side effects, weight gain, agranulocytosis, and seizures (with clozapine)
6. Adequate therapeutic trials: Generally require sufficient dosages over 4-6 weeks
7. Long-term monitoring: Reassess dosage needs dependent on stage of illness

Duration of Treatment

• First-episode patients should receive maintenance psychopharmacological treatment for 1-2 years after the initial episode, given the risk for relapse 1
• The decision to lower dosages or undergo medication-free trials must be balanced against the potential increased risk for relapse 1

Adjunctive Medications

• Some patients may benefit from adjunctive agents including antiparkinsonian agents, mood stabilizers, antidepressants, or benzodiazepines 1
• These are used either to address side effects of the antipsychotic agent or to alleviate associated symptomatology (e.g., agitation, mood instability, dysphoria, explosive outbursts) 1

Psychosocial Interventions

• Adequate treatment requires the combination of psychopharmacological agents PLUS psychosocial interventions 1
• Psychosocial interventions to enhance independent living and social skills should be considered for people with psychotic disorders and their families/caregivers 1
• Facilitation of supported employment may be considered if patients have difficulty obtaining or retaining normal employment 1

Critical Management Principles

• Anticholinergics should NOT be used routinely for preventing extrapyramidal side effects 1
• Short-term use may be considered only when dose reduction and switching strategies have proven ineffective, or when side effects are acute or severe 1
• Individuals on long-term antipsychotic treatment should be given adequate information and encouraged to choose between oral and depot preparations to improve adherence 1

---

Suicide Risk Management

All individuals over 10 years of age with mental disorders, chronic pain, or acute emotional distress should be directly asked about thoughts or plans of self-harm in the last month. 1

Assessment and Intervention

• Direct questioning about suicidal ideation is essential and does not increase risk 1
• A problem-solving approach should be implemented for individuals with self-harm thoughts or behaviors 1
• Social support facilitation is a critical component of suicide prevention 1
• Hospitalization should be considered based on imminent risk assessment 1